---
document_datetime: 2025-11-23 08:01:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/thymanax-0.html
document_name: thymanax-0.html
version: success
processing_time: 0.0608884
conversion_datetime: 2025-12-26 11:07:36.315407
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Thymanax

[RSS](/en/individual-human-medicine.xml/66539)

##### Refused

This medicine has been refused authorisation

agomelatine

Medicine

Human

Refused

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Thymanax](#more-information-on-thymanax-719)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 27 July 2006 the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of a marketing authorisation for the medicinal product Valdoxan/Thymanax, 25 mg film-coated tablets intended for the treatment of major depressive disorder. The company that applied is Les Laboratoires Servier. The applicant requested a reexamination of the opinion, but withdrew this request before the CHMP completed the re-examination.

Questions and answers on the recommendation for the refusal of the marketing authorization for Valdoxan/Thymanax

English (EN) (34.58 KB - PDF)

**First published:** 18/11/2006

**Last updated:** 18/11/2006

[View](/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_en.pdf)

[Other languages (20)](#file-language-dropdown-684)

български (BG) (145.5 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_bg.pdf)

español (ES) (35.29 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_es.pdf)

čeština (CS) (122.08 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_cs.pdf)

dansk (DA) (35.44 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_da.pdf)

Deutsch (DE) (35.92 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_de.pdf)

eesti keel (ET) (34.77 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_et.pdf)

ελληνικά (EL) (141.23 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_el.pdf)

français (FR) (35.35 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_fr.pdf)

italiano (IT) (35.5 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_it.pdf)

latviešu valoda (LV) (144.01 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_lv.pdf)

lietuvių kalba (LT) (118.66 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_lt.pdf)

magyar (HU) (114.79 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_hu.pdf)

Nederlands (NL) (35.41 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_nl.pdf)

polski (PL) (126.21 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_pl.pdf)

português (PT) (35.39 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_pt.pdf)

română (RO) (135.39 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_ro.pdf)

slovenčina (SK) (118.24 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_sk.pdf)

slovenščina (SL) (112.72 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_sl.pdf)

Suomi (FI) (34.66 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_fi.pdf)

svenska (SV) (34.97 KB - PDF)

**First published:**

18/11/2006

**Last updated:**

18/11/2006

[View](/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-valdoxanthymanax_sv.pdf)

## Product details

Name of medicine Thymanax Active substance agomelatine International non-proprietary name (INN) or common name agomelatine Therapeutic area (MeSH) Depressive Disorder, Major

## Application details

EMA product number EMEA/H/C/000657 Marketing authorisation applicant Les Laboratoires Servier Opinion adopted 27/07/2006 Refusal of marketing authorisation 16/01/2007

## Assessment history

Thymanax : EPAR - Refusal public assessment report

Adopted

Reference Number: EMEA/37021/2007 - update

English (EN) (710.39 KB - PDF)

**First published:** 22/10/2007

**Last updated:** 22/10/2007

[View](/en/documents/assessment-report/thymanax-epar-refusal-public-assessment-report_en.pdf)

#### More information on Thymanax

The European Commission initially refused the marketing authorisation for this medicine. Following a later application by the company, the European Commission [granted a marketing authorisation](/en/medicines/human/EPAR/thymanax) for the medicine.

**This page was last updated on** 27/07/2006

## Share this page

[Back to top](#main-content)